Zoetis Inc. (ZTS)

FairStock Score: 74/100 — STEADY

Key Financials

Strengths

• Exceptional 66% ROE demonstrates superior capital allocation and competitive advantages
• Recession-resistant business model with recurring revenue from essential pet and livestock medications
• Strong free cash flow generation of $1.8B annually shows genuine earnings quality
• Market-leading position in fragmented $200B+ global animal health industry
• 25% net profit margin indicates significant pricing power and operational efficiency

Concerns

• Valuation is extreme: 63.9x EV/EBITDA and -672% margin of safety leaves no room for error
• Piotroski F-Score of 4/9 suggests deteriorating financial quality and operational warning signs
• FCF yield of only 1.4% provides minimal return on capital at current price levels
• High debt-to-equity ratio of 2.80 constrains financial flexibility despite quality business

AI Analysis

Zoetis presents an interesting paradox—a quality business at a questionable price. The company operates in a defensive, growing industry: animal health. With a 25% net margin and exceptional ROE of 66%, it demonstrates genuine business quality and pricing power. The pet industry remains recession-resistant, and livestock health solutions benefit from global protein demand. Free cash flow of $1.8B validates earnings quality. However, I cannot ignore the valuation mathematics. At $120.49, Zoetis trades at an EV/EBITDA of 63.9x—extraordinarily expensive even for quality. The Graham Number of $15.60 suggests a margin of safety of -672%, indicating the stock is priced for perfection. The Piotroski F-Score of 4/9 raises questions about accounting quality and operational momentum. While the low debt-to-equity of 2.80 is acceptable, an FCF yield of merely 1.4% is concerning. The business fundamentals are sound: dominant market position, recurring revenue streams, and a 14,500-person global organization generating $2.4B quarterly revenue. Yet I've learned that even great businesses become poor investments at inflated prices. The recent 52-week low of $115.25 suggests minimal downside protection at current levels. For a value investor, this represents a classic case where business quality cannot justify valuation. I'd need to see a significant pullback—ideally toward the $70-80 range—to establish a meaningful margin of safety. Until then, Zoetis remains on my "too expensive to buy, too good to short" list.

Bull Case

Zoetis benefits from structural tailwinds: rising pet ownership in emerging markets, premiumization of pet care spending, and consolidation opportunities in fragmented livestock health. The company's digital and precision health initiatives could drive margin expansion and recurring revenue models that justify premium valuations for decades.

Bear Case

Overvaluation leaves no margin of safety; any earnings disappointment, competitive pressure from generics, or economic slowdown in pet spending would trigger significant correction. The market is pricing in perfection, and Zoetis's 4/9 F-Score suggests momentum is already deteriorating.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer